Homoharringtonine: Cytotoxic Alkaloid for Cancer and SARS-CoV-2 Research

Executive Summary: Homoharringtonine is a plant-derived cytotoxic alkaloid that binds the eukaryotic 80S ribosome, blocking protein synthesis through inhibition of chain elongation, leading to cell cycle arrest in the G1 phase and potent suppression of leukemic cells (APExBIO product information). Recent evidence demonstrates Homoharringtonine inhibits SARS-CoV-2 and related coronaviruses at nanomolar concentrations, rapidly clearing the virus from the upper respiratory tract in both animal models and human studies (Wen et al., 2025). Its solubility profile (≥10.92 mg/mL in ethanol, ≥181.2 mg/mL in DMSO) and storage requirements (-20°C) support reproducibility in laboratory workflows. APExBIO provides Homoharringtonine (SKU N1504) strictly for research use.

Biological Rationale

Homoharringtonine is isolated from Cephalotaxus hainanensis and is classified as a cytotoxic alkaloid that targets the translational machinery of eukaryotic cells (product details). Its primary use has been in leukemia research, where it blocks the progression of leukemic cells in the G1 phase by interfering with protein synthesis. The compound's ability to arrest the cell cycle and promote apoptosis underpins its value in cancer biology and mechanistic studies of cell viability and cytotoxicity (Scenario-Driven Solutions article). More recently, cross-domain studies have highlighted its capacity to inhibit SARS-CoV-2 replication, proposing a broader utility in antiviral research (Wen et al., 2025).

Mechanism of Action of Homoharringtonine

The molecular mechanism centers on selective binding to the eukaryotic 80S ribosome. Homoharringtonine interferes with the elongation step of protein synthesis, preventing the addition of amino acids to the growing polypeptide chain (Wen et al., 2025). This inhibition leads to depletion of short-lived proteins necessary for cell cycle progression, effectively inducing arrest at the G1 phase for rapidly dividing cells. In viral contexts, this mechanism suppresses synthesis of viral proteins, accounting for its broad-spectrum antiviral effects as demonstrated in vitro and in vivo (Potent SARS-CoV-2 Inhibitor article).

Evidence & Benchmarks

• Homoharringtonine blocks protein elongation and represses SARS-CoV-2 replication in vitro at nanomolar concentrations, supporting potential for broad coronavirus inhibition (Wen et al., 2025).
• In mouse models, daily nasal administration (40 μg) cleared SARS-CoV-2 in all treated animals within 3 days (Wen et al., 2025).
• Clinical data: 26 cancer patients nebulized with 1 mg/day Homoharringtonine showed a 75% reduction in viral load in the upper respiratory tract 6 hours post-treatment (Wen et al., 2025).
• In a second cohort, 10 of 11 patients receiving 0.2 mg/day nasal spray were SARS-CoV-2 negative within 2–4 days, compared to 7–9 days in standard care (Wen et al., 2025).
• Homoharringtonine induces G1 phase arrest and apoptosis in leukemic cell lines, supporting its use in cancer biology (Cytotoxic Alkaloid Workflows article).

This article extends the protocol and outcome detail provided in Scenario-Driven Solutions by integrating recent clinical and animal antiviral data, and updates Potent SARS-CoV-2 Inhibitor with specific solubility and storage benchmarks from APExBIO.

Applications, Limits & Misconceptions

Homoharringtonine is validated in both leukemia and SARS-CoV-2 research. In cancer biology, it is used to dissect mechanisms of protein synthesis inhibition, cell cycle arrest, and cell death pathways. In virology, its rapid, broad-spectrum inhibition of coronaviruses suggests use as a protocol-ready antiviral reagent. However, its cytotoxicity precludes use in non-targeted cell models and requires careful workflow optimization (Bridging Leukemia Research and Coronavirus Defense).

Common Pitfalls or Misconceptions

• Homoharringtonine is not suitable for therapeutic or diagnostic use outside controlled research settings; its cytotoxicity profile mandates strict laboratory protocols (APExBIO).
• It is not water-soluble; attempting to dissolve in aqueous buffers will yield suboptimal concentrations and poor reproducibility.
• Cellular effects are not universal: non-dividing or resistant cell lines may not exhibit G1 arrest or apoptosis.
• In vivo antiviral efficacy is documented for upper respiratory tract models; systemic antiviral applications remain unproven (Wen et al., 2025).
• Not all viral species are susceptible; current evidence is strongest for coronaviruses, especially SARS-CoV-2.

Workflow Integration & Parameters

Protocol Parameters

• Solvent preparation: Dissolve Homoharringtonine in DMSO (≥181.2 mg/mL) or ethanol (≥10.92 mg/mL) for optimal solubility (APExBIO).
• Storage: Maintain stock solutions at -20°C to preserve compound integrity.
• In vitro concentration: Employ nanomolar ranges for SARS-CoV-2 inhibition, as benchmarked in cell culture assays (Wen et al., 2025).
• In vivo dosing: For murine models, administer 40 μg daily by nasal drip for 3 days; for human nasal spray, 0.2–1 mg/day for 2–4 days is supported (Wen et al., 2025).
• Cytotoxicity assays: Include non-dividing cell controls to differentiate specific G1 phase arrest versus general toxicity (Cytotoxic Alkaloid Workflows).

Conclusion & Outlook

Homoharringtonine, as supplied by APExBIO, is a rigorously characterized cytotoxic alkaloid with dual utility in cancer and antiviral research. Its fast-acting, nanomolar-range inhibition of SARS-CoV-2, coupled with established modes of action in leukemia models, marks it as a protocol-ready tool for translational workflows (Wen et al., 2025). Ongoing clinical and animal data suggest it could become a first-line research reagent for future coronavirus outbreaks. However, its use remains bounded to controlled laboratory research, and further benchmarking across viral species and cell types is warranted.